MX385287B - Anticuerpos anti-puntos de control inmunitarios para usarse en el tratamiento de la enfermedad de alzheimer. - Google Patents

Anticuerpos anti-puntos de control inmunitarios para usarse en el tratamiento de la enfermedad de alzheimer.

Info

Publication number
MX385287B
MX385287B MX2016011832A MX2016011832A MX385287B MX 385287 B MX385287 B MX 385287B MX 2016011832 A MX2016011832 A MX 2016011832A MX 2016011832 A MX2016011832 A MX 2016011832A MX 385287 B MX385287 B MX 385287B
Authority
MX
Mexico
Prior art keywords
disease
treatment
alzheimer
immune checkpoint
therapy
Prior art date
Application number
MX2016011832A
Other languages
English (en)
Other versions
MX2016011832A (es
Inventor
Michal Eisenbach-Schwartz
Kuti Baruch
Neta Rosenzweig
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of MX2016011832A publication Critical patent/MX2016011832A/es
Publication of MX385287B publication Critical patent/MX385287B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica para usarse en el tratamiento de la enfermedad de Alzheimer en un individuo, en donde la composición farmacéutica comprende un agente activo que causa reducción del nivel de inmunosupresión sistémica en un individuo, en donde el agente activo se selecciona de un anticuerpo anti-PD-1,anticuerpo anti-PD-L1, anticuerpo anti-TIM-3, o una combinación de los mismos, y en donde la composición farmacéutica está adaptada para ser administrable mediante un régimen de dosificación que causa reducción transitoria del nivel de la inmunosupresión sistématica que comprende por lo menos dos cursos de terapia, cada curso de terapia comprende en secuencia una sesión de tratamiento que comprende la administración de la composición farmacéutica al individuo, seguido de una sesión de no tratamiento en la que la composición farmacéutica no es administrable al individuo, en donde la sesión de tratamiento es de entre 3 días y cuatro semanas y seis meses de duración, entre dos semanas y seis meses de duración, o entre tres semanas y seis meses de duración.
MX2016011832A 2014-03-12 2015-03-12 Anticuerpos anti-puntos de control inmunitarios para usarse en el tratamiento de la enfermedad de alzheimer. MX385287B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461951783P 2014-03-12 2014-03-12
US201462030164P 2014-07-29 2014-07-29
PCT/IL2015/050265 WO2015136541A2 (en) 2014-03-12 2015-03-12 Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns

Publications (2)

Publication Number Publication Date
MX2016011832A MX2016011832A (es) 2017-05-12
MX385287B true MX385287B (es) 2025-03-18

Family

ID=53488381

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016011832A MX385287B (es) 2014-03-12 2015-03-12 Anticuerpos anti-puntos de control inmunitarios para usarse en el tratamiento de la enfermedad de alzheimer.
MX2018000466A MX2018000466A (es) 2014-03-12 2016-07-13 Reducción de niveles o de actividad de células t regulatorias sistémicas para el tratamiento de enfermedad y lesión del sistema nervioso central (snc).
MX2021009611A MX2021009611A (es) 2014-03-12 2016-09-12 Reduccion de los niveles o la actividad de las celulas t reguladoras sistemicas para el tratamiento de enfermedad y lesion del sistema nervioso central (snc).

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2018000466A MX2018000466A (es) 2014-03-12 2016-07-13 Reducción de niveles o de actividad de células t regulatorias sistémicas para el tratamiento de enfermedad y lesión del sistema nervioso central (snc).
MX2021009611A MX2021009611A (es) 2014-03-12 2016-09-12 Reduccion de los niveles o la actividad de las celulas t reguladoras sistemicas para el tratamiento de enfermedad y lesion del sistema nervioso central (snc).

Country Status (14)

Country Link
US (16) US10144778B2 (es)
EP (3) EP4635508A2 (es)
JP (7) JP6903432B2 (es)
KR (4) KR20200029627A (es)
CN (2) CN114081946A (es)
AU (5) AU2015228372B2 (es)
BR (2) BR112016020919A2 (es)
CA (2) CA3129892C (es)
ES (1) ES3040431T3 (es)
IL (2) IL256792B2 (es)
MX (3) MX385287B (es)
NZ (2) NZ747418A (es)
RU (2) RU2690670C2 (es)
WO (2) WO2015136541A2 (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN114081946A (zh) 2014-03-12 2022-02-25 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
WO2017042633A2 (en) * 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
US9394365B1 (en) * 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) * 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10227408B2 (en) 2015-02-19 2019-03-12 Compugen Ltd. Anti-PVRIG antibodies and methods of use
EP3461337A1 (en) 2015-05-06 2019-04-03 Snipr Technologies Limited Altering microbial populations & modifying microbiota
CN115109158A (zh) 2015-05-07 2022-09-27 阿吉纳斯公司 抗ox40抗体及其使用方法
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
SG10202101909RA (en) 2015-08-07 2021-04-29 Alx Oncology Inc Constructs having a sirp-alpha domain or variant thereof
KR101785155B1 (ko) * 2015-09-22 2017-10-16 국립암센터 Ｔｉｍ－３을 표적으로 하는 뇌손상 질환 치료용 조성물 및 이의 스크리닝 방법
EP3355920A4 (en) 2015-09-29 2019-05-15 Celgene Corporation PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods of use thereof
UA124529C2 (uk) 2016-01-08 2021-10-05 Аркус Байосайєнсіз, Інк. Модулятори екто-5-нуклеотидази та їх застосування
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
HRP20211820T1 (hr) 2016-04-12 2022-03-04 Symphogen A/S Anti-tim-3 protutijela i pripravci
KR20230091191A (ko) 2016-05-27 2023-06-22 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
EP3481402A4 (en) 2016-07-06 2020-01-22 Sperovie Biosciences, Inc. CONNECTIONS, COMPOSITIONS AND METHODS FOR TREATING A DISEASE
KR20230044038A (ko) 2016-08-09 2023-03-31 키맵 리미티드 항-icos 항체
CN116492457A (zh) * 2016-09-10 2023-07-28 耶达研究与开发有限公司 降低全身调节性t细胞水平或活性以治疗中枢神经系统的疾病和损伤
US11453726B2 (en) 2016-09-15 2022-09-27 Quadrucept Bio Limited Multimers, tetramers and octamers
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
AU2017329024A1 (en) 2016-09-19 2019-03-21 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
BR112019007369A2 (pt) 2016-10-11 2019-07-16 Agenus Inc anticorpos anti-lag-3 e métodos de uso dos mesmos
US11166995B2 (en) 2016-11-01 2021-11-09 Osaka University Anticancer agent comprising HVJ-E and immune checkpoint protein inhibitor
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018089628A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
US11230596B2 (en) 2016-11-30 2022-01-25 Mereo Biopharma 5, Inc. Methods for treatment of cancer comprising TIGIT-binding agents
ES2896255T3 (es) * 2016-12-06 2022-02-24 Univ Osaka Nuevo agente terapéutico para enfermedades por prionoides
AU2018247916B2 (en) 2017-04-05 2025-04-24 Les Laboratoires Servier Combination therapies targeting PD-1, TIM-3, and LAG-3
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
EP3618863B1 (en) 2017-05-01 2023-07-26 Agenus Inc. Anti-tigit antibodies and methods of use thereof
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
JP7158677B2 (ja) * 2017-06-30 2022-10-24 小野薬品工業株式会社 溶血性レンサ球菌の菌体を含む製剤との併用療法
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
WO2019046511A1 (en) 2017-08-31 2019-03-07 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
WO2019051489A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
EP3456819A1 (en) * 2017-09-13 2019-03-20 Trizell GmbH Regulatory macrophages for the treatment of angopathies
US20190160120A1 (en) 2017-11-29 2019-05-30 Snipr Biome Aps Dna, methods etc
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3773685A1 (en) 2018-03-25 2021-02-17 SNIPR Biome ApS. Treating & preventing microbial infections
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
US20210077477A1 (en) * 2018-03-27 2021-03-18 Raz Yirmiya Microglia modulators for use in treatment of depression
CN120714025A (zh) 2018-06-20 2025-09-30 因赛特公司 抗pd-1抗体及其用途
EP3820477A4 (en) 2018-07-10 2022-07-13 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
CN115227824A (zh) * 2018-11-12 2022-10-25 中南大学湘雅二医院 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用
US20220146534A1 (en) * 2019-01-16 2022-05-12 Yeda Research And Development, Co., Ltd. Biomarkers for CNS Disease Modification
GB201901099D0 (en) 2019-01-27 2019-03-13 Snipr Biome Aps Methods, uses and compositions
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND USES THEREOF
EP4592313A3 (en) * 2019-03-05 2025-11-19 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
GB201906668D0 (en) 2019-05-12 2019-06-26 Folium Food Science Ltd Antibacterial agents
GB201907242D0 (en) 2019-05-22 2019-07-03 Snipr Biome Aps Dna methods etc ii
AU2020282791A1 (en) 2019-05-31 2021-12-09 ALX Oncology Inc. Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor
GB201912176D0 (en) 2019-08-23 2019-10-09 Snipr Biome Aps Plasmids
WO2021098750A1 (en) * 2019-11-21 2021-05-27 Beigene (Beijing) Co., Ltd. Methods of cancer treatment with anti-ox40 antibody in comibinaiton with tlr agonists
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
GB202007943D0 (en) 2020-05-27 2020-07-08 Snipr Biome Aps Products & methods
GB202015255D0 (en) 2020-09-26 2020-11-11 Snipr Biome Aps Synthetic viruses
GB202017618D0 (en) 2020-11-08 2020-12-23 Folium Food Science Ltd Antibacterial methods & cells
JP2024508658A (ja) 2021-02-04 2024-02-28 ジェヌーヴ インク． 抗ｐｄ－１抗体及びその用途
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
EP4337190A1 (en) 2021-05-13 2024-03-20 ALX Oncology Inc. Combination therapies for treating cancer
CA3219336A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
WO2023077016A1 (en) * 2021-10-28 2023-05-04 Baylor College Of Medicine Targeting neuronal sirpα for treatment and prevention of neurological disorders
FR3136481A1 (fr) 2021-12-17 2023-12-15 Snipr Biome Aps Procedes et compositions d'apport d'acide nucleique
CN114984219B (zh) * 2022-03-29 2023-06-27 浙江大学 Pd1抑制剂在制备心脏成纤维细胞转分化抑制剂中的用途
EP4525991A1 (en) 2022-05-18 2025-03-26 Kymab Limited Uses of anti-icos antibodies
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
GB202212688D0 (en) 2022-08-31 2022-10-12 Snipr Biome Aps A novel type of crispr/cas system
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells
WO2025046062A1 (en) 2023-08-31 2025-03-06 Snipr Biome Aps A novel type of crispr/cas system

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
IL140592A0 (en) 1998-07-23 2002-02-10 Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
ES2248283T3 (es) * 2000-02-21 2006-03-16 Pharmexa A/S Nuevo procedimiento para reducir los niveles de amiloide.
US20040033497A1 (en) * 2002-08-13 2004-02-19 Alarcon-Riquelme Marta E. Polymorphisms of PD-1
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
EP1438061B1 (en) 2001-10-03 2016-05-11 President and Fellows of Harvard College Copolymers for suppression of autoimmune diseases, and methods of use
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
WO2004072286A1 (ja) 2003-01-23 2004-08-26 Ono Pharmaceutical Co., Ltd. ヒトｐｄ−１に対し特異性を有する物質
KR20060089732A (ko) * 2003-10-03 2006-08-09 브라이엄 앤드 위민즈 하스피틀 Ｔｉｍ-3 리간드 및 그의 방법
SI1694360T1 (sl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostic Uporaba antagonističnih anti-CD40 protiteles za zdravljenje avtoimunskih in vnetnih bolezni in zavrnitve transplantata organa
EP1684797A1 (en) * 2003-11-12 2006-08-02 Yeda Research and Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
GB0400440D0 (en) 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
GB0503434D0 (en) * 2005-02-18 2005-03-30 Senexis Ltd Amyloid-binding peptides, analogues and uses thereof
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101888321B1 (ko) * 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
AU2006308860B2 (en) 2005-11-01 2012-01-12 Novartis Ag Uses of anti-CD40 antibodies
CA2668693A1 (en) 2006-11-15 2008-05-22 David E. Anderson Therapeutic uses of tim-3 modulators
JP2010522772A (ja) * 2007-03-28 2010-07-08 バイオジェン・アイデック・インコーポレイテッド 腫瘍微小環境の調整
CA2688275A1 (en) * 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
DK2238166T3 (da) 2007-10-05 2014-01-27 Ac Immune Sa Anvendelse af et anti-amyloid-beta-antistof ved øjensygdomme
US8629098B2 (en) 2008-01-15 2014-01-14 Yale University Compositions and methods for adoptive and active immunotherapy
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
WO2010029435A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
MX2011003195A (es) 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
CN102216448A (zh) * 2008-11-13 2011-10-12 分子医学研究院 Foxp3+天然杀伤t细胞及免疫相关疾病的治疗
AU2009324092A1 (en) 2008-12-03 2011-06-23 Genmab A/S Antibody variants having modifications in the constant region
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
PT2398498T (pt) * 2009-02-17 2018-12-03 Ucb Biopharma Sprl Moléculas de anticorpo tendo especificidade para ox40 humano
KR20120101053A (ko) * 2009-11-06 2012-09-12 더 제이. 데이비드 글래드스톤 인스티튜트 타우 레벨을 조절하기 위한 방법 및 조성물
CA2791930A1 (en) * 2010-03-11 2011-09-15 Kerry Louise Tyson Pd-1 antibody
CA2792754C (en) 2010-03-12 2019-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services .beta.-mannosylceramide and stimulation of nkt cell anti-tumor immunity
US10745467B2 (en) * 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
PE20180042A1 (es) * 2010-08-23 2018-01-09 Univ Texas Anticuerpos anti-ox40 y metodos de uso de los mismos
US20130323283A1 (en) * 2010-12-01 2013-12-05 The Children's Hospital Of Philadelphia Compositions and methods for treating foxp3+ treg related diseases
EP2686020B1 (en) 2011-03-17 2017-02-22 The University of Birmingham Re-directed immunotherapy
AU2012232658B2 (en) 2011-03-22 2016-06-09 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
AU2012236479B2 (en) 2011-03-31 2016-10-20 Merck Sharp & Dohme Llc Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
ES2669310T3 (es) 2011-04-20 2018-05-24 Medimmune, Llc Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
HRP20180858T1 (hr) * 2011-07-11 2018-09-21 Glenmark Pharmaceuticals S.A. Protutijela koja se vežu na ox40 i njihove uporabe
EP3321281B1 (en) * 2011-08-05 2019-11-27 biOasis Technologies Inc P97 fragments with transfer activity
EP3939613A1 (en) 2011-08-11 2022-01-19 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
JP6038920B2 (ja) * 2011-08-23 2016-12-07 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗ｏｘ４０抗体およびそれを使用する方法
CA2853823C (en) 2011-10-28 2016-12-20 Integritybio Inc. Protein formulations containing amino acids
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2013142255A2 (en) 2012-03-22 2013-09-26 University Of Miami Multi-specific binding agents
CA3132353A1 (en) 2012-05-08 2013-11-14 The Johns Hopkins University Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
IN2014KN00920A (es) 2012-06-21 2015-10-09 Compugen Ltd
BR112014032276A2 (pt) 2012-06-22 2017-11-28 King S College London construtos de vista-ig e o uso de vista-ig para o tratamento de distúrbios autoimunes, alérgicos e inflamatórios
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
WO2014022332A1 (en) * 2012-07-31 2014-02-06 The Brigham And Women's Hospital, Inc. Modulation of the immune response
WO2014028502A1 (en) 2012-08-13 2014-02-20 ImmunGene Inc. Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014037952A1 (en) * 2012-09-10 2014-03-13 Yeda Research And Development Co. Ltd At The Weizmann Institute Of Science Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia
JP2015529242A (ja) 2012-09-21 2015-10-05 アドヴィヌス セラピューティクス リミテッドＡｄｖｉｎｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 置換された縮合三環式化合物、組成物およびその医薬用途
KR20150075082A (ko) 2012-10-09 2015-07-02 산바이오 인코포레이티드 망막 변성의 치료 방법 및 치료용 조성물
CA3201072A1 (en) 2012-10-12 2014-04-17 The Brigham And Women's Hospital, Inc. Enhancement of the immune response
AU2013334610B2 (en) 2012-10-24 2018-09-13 Novartis Ag IL-15R alpha forms, cells expressing IL-15R alpha forms, and therapeutic uses of IL-15R alpha and IL-15/IL-15R alpha complexes
EP2914278B1 (en) 2012-11-05 2021-06-02 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
WO2014074852A1 (en) 2012-11-09 2014-05-15 President And Fellows Of Harvard College Compositions and methods for modulating an immune response
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US8877202B2 (en) 2013-02-07 2014-11-04 Immunomedics, Inc. Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
SG10201710473VA (en) 2013-02-22 2018-02-27 Curevac Ag Combination of vaccination and inhibition of the pd-1 pathway
RU2019138702A (ru) 2013-03-01 2020-01-27 Астекс Фармасьютикалз, Инк. Комбинации лекарственных средств
BR112015023256A2 (pt) 2013-03-13 2017-07-18 Oncoceutics Inc terapia de combinação com 7-benzil-10-(2-metil-benzil)-2,6,7,8,9,10-hexaidroimidazol[1,2-a]pirido[4,3-d]pirimidin-5(3h)-ona.
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
MA38461B1 (fr) 2013-03-14 2021-10-29 Curadev Pharma Private Ltd Inhibiteurs de la voie de la kynurénine
JP6596411B2 (ja) 2013-03-14 2019-10-23 アイカーン スクール オブ メディシン アット マウント サイナイ ニューカッスル病ウイルス及びその使用
US10745483B2 (en) 2013-03-15 2020-08-18 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
MX369709B (es) 2013-03-15 2019-11-19 Univ Pennsylvania Vacunación mejorada contra tirosinasa.
ES2699599T3 (es) 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Variantes de Fc
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10047137B2 (en) 2013-04-05 2018-08-14 Versitech Limited Antibodies against novel PD1 isoforms and uses thereof
SG11201508528TA (en) 2013-05-02 2015-11-27 Anaptysbio Inc Antibodies directed against programmed death-1 (pd-1)
AU2014262469B2 (en) 2013-05-10 2019-11-14 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
CN111423511B (zh) 2013-05-31 2024-02-23 索伦托药业有限公司 与pd-1结合的抗原结合蛋白
EP3650038A1 (en) 2013-06-19 2020-05-13 Massachusetts Institute of Technology In vivo targeting of cells with ligand-conjugated particles
EP3010507A4 (en) 2013-06-22 2017-06-07 Nitor Therapeutics Compositions and methods for potentiating immune response for the treatment of infectious diseases and cancer
US20160145355A1 (en) 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
SG11201600310QA (en) 2013-07-16 2016-02-26 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
PL3444271T3 (pl) 2013-08-08 2022-03-07 Cytune Pharma Modulokiny oparte na il-15 i domenie sushi il-15ralfa
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
US20160200814A1 (en) 2013-08-22 2016-07-14 The Council Of The Queensland Institute Of Medical Research Immunoreceptor modulation for treating cancer and viral infections
NZ717534A (en) 2013-08-22 2022-04-29 Council Queensland Inst Medical Res Immunoreceptor modulation for treating cancer and viral infections
US10077305B2 (en) 2013-09-10 2018-09-18 Medimmune Limited Antibodies against PD-1 and uses thereof
CA2922805A1 (en) * 2013-09-11 2015-03-19 Compugen Ltd. Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
PT3702373T (pt) 2013-09-13 2022-09-27 Beigene Switzerland Gmbh Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico
EP3060251A4 (en) 2013-10-25 2017-12-06 Pharmacyclics LLC Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
CN104558177B (zh) 2013-10-25 2020-02-18 苏州思坦维生物技术股份有限公司 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
US20150165021A1 (en) 2013-11-05 2015-06-18 Nkt Therapeutics Inc. Combination therapy
US20160375041A1 (en) 2013-12-02 2016-12-29 David A. TABACZYNSKI Inhibition of isoprenoid biosynthetic pathways to treat autoimmune disorders
WO2015082499A2 (en) 2013-12-03 2015-06-11 Iomet Pharma Ltd Pharmaceutical compound
US10106611B2 (en) 2013-12-06 2018-10-23 Dana-Farber Cancer Institute, Inc. Antibodies that bind to MHC class I polypeptide-related sequence A
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
PE20210107A1 (es) 2013-12-17 2021-01-19 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
US10494434B2 (en) 2013-12-20 2019-12-03 Fred Hutchinson Cancer Research Center Tagged chimeric effector molecules and receptors thereof
DK3089994T3 (da) 2013-12-30 2022-07-04 Epimab Biotherapeutics Inc Fabs-in-tandem-immunglobulin og anvendelser deraf
EP3092004A4 (en) 2014-01-06 2017-02-22 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) * 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
WO2017042633A2 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
CN114081946A (zh) 2014-03-12 2022-02-25 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
WO2017009853A1 (en) * 2015-07-16 2017-01-19 Yeda Research And Development Co. Ltd. Genetically modified anti-third party central memory t cells and use of same in immunotherapy
WO2017040301A1 (en) 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
CN109563171B (zh) 2016-06-20 2023-09-19 F-星治疗有限公司 结合pd-l1和lag-3的结合分子
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018134824A1 (en) * 2017-01-18 2018-07-26 Yeda Research And Development Co. Ltd. Genetically modified veto cells and use of same in immunotherapy
US20220146534A1 (en) * 2019-01-16 2022-05-12 Yeda Research And Development, Co., Ltd. Biomarkers for CNS Disease Modification
EP3725370A1 (en) * 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease

Also Published As

Publication number Publication date
AU2016293498B2 (en) 2022-01-13
US20180111997A1 (en) 2018-04-26
US9512227B2 (en) 2016-12-06
US20240182566A1 (en) 2024-06-06
US10961309B2 (en) 2021-03-30
ES3040431T3 (en) 2025-10-31
NZ747418A (en) 2023-05-26
KR102248804B1 (ko) 2021-05-11
US20160311905A1 (en) 2016-10-27
US9512225B2 (en) 2016-12-06
US9982050B2 (en) 2018-05-29
US20160297880A1 (en) 2016-10-13
EP3116542A2 (en) 2017-01-18
AU2022202797B2 (en) 2025-03-27
AU2016293498A1 (en) 2018-03-01
IL256792B2 (en) 2023-11-01
JP2020040976A (ja) 2020-03-19
IL247747A0 (en) 2016-11-30
IL256792B1 (en) 2023-07-01
US11884727B2 (en) 2024-01-30
US10214585B2 (en) 2019-02-26
EP3116542C0 (en) 2025-07-30
JP2023089119A (ja) 2023-06-27
NZ725006A (en) 2019-11-29
MX2018000466A (es) 2018-11-09
CA3129892A1 (en) 2015-09-17
AU2015228372B2 (en) 2018-05-31
US20160008463A1 (en) 2016-01-14
US9982051B2 (en) 2018-05-29
JP6903432B2 (ja) 2021-07-14
US20190185563A1 (en) 2019-06-20
CN114081946A (zh) 2022-02-25
WO2017009829A1 (en) 2017-01-19
US20210188977A1 (en) 2021-06-24
US20160000909A1 (en) 2016-01-07
US20160319021A1 (en) 2016-11-03
US20170240634A1 (en) 2017-08-24
MX2021009611A (es) 2021-09-08
BR112016020919A2 (pt) 2018-01-23
US20180105592A1 (en) 2018-04-19
JP2017512771A (ja) 2017-05-25
JP2022163730A (ja) 2022-10-26
JP2025102963A (ja) 2025-07-08
WO2015136541A2 (en) 2015-09-17
EP4591880A3 (en) 2025-11-05
CA2991981A1 (en) 2017-01-19
KR20200029627A (ko) 2020-03-18
KR20180030128A (ko) 2018-03-21
RU2018104962A (ru) 2019-08-13
US9982049B2 (en) 2018-05-29
US20210221888A1 (en) 2021-07-22
AU2018220155B2 (en) 2019-12-05
EP4591880A2 (en) 2025-07-30
AU2015228372A1 (en) 2016-10-27
RU2016139974A3 (es) 2018-10-12
MX2016011832A (es) 2017-05-12
RU2016139974A (ru) 2018-04-12
CN106687125A (zh) 2017-05-17
RU2741366C2 (ru) 2021-01-25
CA2942245A1 (en) 2015-09-17
US20180118826A1 (en) 2018-05-03
US9982047B2 (en) 2018-05-29
JP2018524362A (ja) 2018-08-30
US20180111998A1 (en) 2018-04-26
WO2015136541A3 (en) 2015-11-12
US20180111999A1 (en) 2018-04-26
RU2690670C2 (ru) 2019-06-05
IL247747B (en) 2020-08-31
US10144778B2 (en) 2018-12-04
BR112018000646A2 (pt) 2018-12-11
AU2020201602B2 (en) 2022-02-03
US11884728B2 (en) 2024-01-30
US9856318B2 (en) 2018-01-02
AU2018220155A1 (en) 2018-09-13
KR20230097209A (ko) 2023-06-30
CN106687125B (zh) 2021-12-14
EP4635508A2 (en) 2025-10-22
CA3129892C (en) 2025-11-18
US10981989B2 (en) 2021-04-20
IL256792A (en) 2018-03-29
AU2022202797A1 (en) 2022-05-19
US9534052B2 (en) 2017-01-03
CA2942245C (en) 2021-11-02
EP3116542B1 (en) 2025-07-30
JP6867367B2 (ja) 2021-04-28
AU2020201602A1 (en) 2020-03-19
JP2021107412A (ja) 2021-07-29
US20190112371A1 (en) 2019-04-18
US9982048B2 (en) 2018-05-29
RU2018104962A3 (es) 2020-02-04
KR20160133510A (ko) 2016-11-22

Similar Documents

Publication Publication Date Title
MX385287B (es) Anticuerpos anti-puntos de control inmunitarios para usarse en el tratamiento de la enfermedad de alzheimer.
MX2024004439A (es) Agentes terapeuticos para enfermedades neurodegenerativas
MX383399B (es) Un antagonista anti-vegf para usarse en el tratamiento de enfermedades oculares.
ZA201903091B (en) Methods of treating inflammatory conditions
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
WO2015187998A3 (en) Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2020005166A (es) Uso de un antagonista de vegf para tratar trastornos oculares angiogenicos.
EP4269439A3 (en) Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
MX379043B (es) Uso de sobetirome en el tratamiento de enfermedades de mielinización.
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam
WO2017042633A3 (en) Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
MX2019014483A (es) Regimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para el tratamiento de endometriosis.
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
MX2019010982A (es) Uso de receptores de diseño activados exclusivamente mediante fármacos de diseño en el tratamiento de trastornos convulsivos.
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
HK1243368A1 (zh) 丁丙诺啡给药方案
MX2020003427A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
HK1246288A1 (zh) S1pr2拮抗剂及其用途
MX389844B (es) Regimen de dosificacion para interferon pegilado.
EA201792314A1 (ru) Фармацевтическая комбинация эверолимуса и дактолисиба
EA201691562A2 (ru) Фильтры для инфузионных наборов
HK1233504A1 (en) Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
AR102494A1 (es) Métodos para tratar enfermedades oculares